Mineralis Therapeutics tracks a December 22nd PDUFA date for lorunderstat and readiness for a 2027 launch. It stated $625 million in capital, including a $500 million secured facility with $100 million drawn.
MLYS · Mineralys Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Mineralis Therapeutics is preparing for potential Lerunderstat approval after its December 22nd PDUFA target date, with launch preparations advancing and $624.7 million in cash, cash equivalents, and investments funding operations into 2028.
Mineralys Therapeutics said the FDA accepted its lorundrostat NDA for hypertension, with a PDUFA target date of December 22, 2026.
Mineralys said lorundrostat remains on track for a December 22, 2026 PDUFA target date. Third-quarter net loss was $57.3 million, and cash, cash equivalents and investments were $624.7 million as of September 30, 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q3 FY26 earnings call · Nov 4, 2026TL;DR. Ahead of the December 22, 2026 PDUFA date, launch preparations are on track, while Launch-HTN and Explore-OSA showed favorable blood-pressure results and long-term TRANSFORM-HTN data are scheduled for presentation. Current liquidity is expected to fund operations and the commercial launch into 2028. The company also reported higher G&A expense, a larger net loss, lower liquidity, higher interest expense, and no measurable change in the Explore-OSA apnea-hypopnea index.
- + Commercial launch readiness advanced with an expanded medical affairs team, a sales force in place, payer engagement, brand marketing underway, and a patient support program being finalized.
- + New long-term efficacy and safety data from TRANSFORM-HTN are scheduled for a late-breaking presentation at the American Heart Association Scientific Sessions 2026.
- + Current liquidity is expected to fund planned operations and the commercial launch into 2028.
- + R&D expense decreased to $22.7 million from $31.5 million in the prior-year quarter.
- − Net loss increased to $57.3 million from $36.9 million in the prior-year quarter.
- − Cash, cash equivalents, and investments declined to $624.7 million from $656.6 million at year-end 2025.
- − Interest expense increased by $3.2 million due to the senior secured term loan entered into in June 2026.
- − Explore-OSA produced no measurable change in the apnea-hypopnea index.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MLYS
this stock
Mineralys Therapeutics, Inc.
|
$1.29B | -60.0% | — | — | 8.7% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.35B | +18.6% | +46.2% | 34.6 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.52B | +23.4% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$87.10B | +630.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$65.26B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 25
Mineralis Therapeutics tracks a December 22nd PDUFA date for lorunderstat and readiness for a 2027 launch. It stated $625 million in capital, including a $500 million secured facility with $100 million drawn.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MLYS | -8.1% | -30.5% | -51.6% | -20.1% | -60.0% |
| SPY | -1.7% | -3.5% | -1.4% | -2.1% | +8.5% |
| vs SPY | -6.4% | -27.1% | -50.2% | -18.0% | -68.5% |